PubMed Health⌕ Search

Biomedical subjects

G Baumgartner

Publications and source records attributed to G Baumgartner.

At least 91 records · Page 5Linked to original sources
PubMed1981

Urinary immunoglobulin A in the diagnosis of bladder cancer.

Urinary immunoglobulin A levels were measured in the urine of 13 patients with histologically diagnosed bladder cancer present, six patients with culture proven urinary tract infection, and 14 control individuals. There were statistically significantly higher immunoglobulin A levels in the urine of patients with bladder cancer than in either individuals with urinary tract infection or control individuals. Urinary immunoglobulin A may be a potentially useful test for the diagnosis and follow-up of bladder cancer patients.

Follow-Up Studies↗
PubMed1981

[Hyperparathyreoidism and chronic lymphocytic leukemia (author's transl)].

A 55 year old patient with chronic lymphocytic leukemia is reported in whom hypercalcemia occurred associated with hypophosphatemia and elevated parathyroid hormone levels (C-terminal assay). Bone histology gave further evidence for hyperparathyroidism. During neck and mediastinal exploration numerous lymph nodes were exstirpated. Although pathologic parathyroid tissue could not be identified it is concluded from postoperative normalisation of calcium levels that hyperparathyroidism had been cured by surgery. The patient died the seventh postoperative day on bronchopulmonary infection. Early differential diagnostic evaluation of the rare symptom hypercalcemia in chronic lymphocytic leukemia is postulated.

Diagnosis, Differential↗
PubMed1980

[Methotrexate citrovorum factor therapy in advanced hypernephromas (author's transl)].

MTX-CF therapy was administered in 13 patients with advanced renal cell carcinoma. 2 patients were treated with MTX single agent therapy at a dosage of up to 750mg/m2 per cycle and a short CF rescue of 48 hours. They showed partial remissions along with severe toxicity including gastrointestinal symptoms and bone marrow depression. 11 patients were treated by combination of MTX/CF, vincristine, bleomycin and an alkylating agent (either peptichemio or cyclophosphamide). In this latter group, patients with a glomerular filtration rate of more than 70 ml/min received 150 to 400 mg/m2 per cycle MTX. Patients with decreased renal function (glomerular filtration rate less than 70 ml/min) received 35 to 100 mg/m2 per cycle MTX. Two out of 7 patients with decreased glomerular filtration rate achieved remissions of more than 50%, two achieved remissions of less than 50% and two patients achieved static disease. Only one patient in the group of 4 patients with normal renal function showed a remission of more than 50%. Median survival time of patients in partial remission or with static disease was 24 months, of patients showing progression was 5 months. This difference is highly significant (p < 0.001). These results seem to justify further investigations of MTX/CF therapy in hypernephromas, even in the presence of impaired renal function.

Adenocarcinoma↗
PubMed1980

The immune response to prostate cancer: an evaluation and a review.

The effects of stage and therapy of prostate cancer on the immune response were evaluated in 193 patients with an histologic diagnosis of prostatic malignancy. There was little or no effect, as measured by these generally non-specific tests, on the immune response. The host-tumor immune interaction is difficult to evaluate in prostate cancer. The complexities of measuring prostate tumor immunity are discussed and the literature is reviewed.

Adenocarcinoma↗
PubMed1980

Screening tests for detection of bladder cancer.

Eighty-one individuals had urine cytologic studies, urinary carcinoembryonic antigen (CEA) determinations, and urinary immunoglobulin levels performed to evaluate various screening tests for the diagnosis of bladder cancer. Urinary cytologic studies detect the presence of bladder malignancy, and while false positive tests were troublesome, remain the primary screening test for bladder cancer. Urinary CEA was of little value in detecting vesical malignancy. Urinary immunoglobulins, particularly IGG and IGA, were significantly elevated in the presence of bladder cancer.

Carcinoembryonic Antigen↗
PubMed1980

Methotrexate-citrovorum factor used alone and in combination chemotherapy for advanced hypernephromas.

Methotrexate-citrovorum factor (MTX-CF) therapy was administered to 20 patients with advanced renal cell carcinoma. Eight patients were treated with MTX-CF only. Two patients who received short-term rescue showed partial remissions along with severe toxicity including gastrointestinal symptoms and bone marrow depression. Twelve patients were treated with a combination of MTX-CF, vincristine, bleomycin, and an alkylating agent (either peptichemio or cyclophosphamide). In this latter group, patients with a glomerular filtration rate of greater than 70 ml/minute received 150-400 mg/m2/cycle of MTX. Patients with decreased renal function (less than 70 ml/minute) received 35-100 mg/m2/cycle of MTX. Two of seven patients with a decreased glomerular filtration rate showed partial remissions and four patients had static disease. One patient in the group of five with normal renal function showed static disease. None showed objective improvement. The median survival time was 25 months for patients with partial remission and static disease and 4.75 months for patients with progression. This difference is highly significant (P less than 0.0005). These results seem to justify further investigations of MTX-CF therapy in hypernephromas, even in the presence of impaired renal function.

Adenocarcinoma↗
PubMed1979

Right/left differences of median nerve evoked scalp potentials in multiple sclerosis.

Scalp potentials evoked by electrical stimulation of the median nerve at the wrist were examined in multiple sclerosis patients and healthy controls. The latencies of the first negative peak (about 18 ms latency) of the response to right and to left-sided stimulation were compared. Forty-eight of 60 measured latency differences in 15 suspected or certain MS patients were more than 3 standard deviations beyond the average difference in controls (arbitrary norm limit), whereas none of the 56 results of the 14 controls was in that range. Fifteen of 24 latency differences in 6 patients without anamnestic or clinical sensory disturbances in the arms were above the limit. On the other hand, conduction velocity between wrist, neck and scalp did not differentiate controls from patients. We suggest using latency differences of the early components of right and left median nerve-evoked scalp potentials as a mean for the early detection of functional disturbances in multiple sclerosis.

Adult↗
PubMed1979

Adjuvant immunotherapy with bacillus Calmette-Guérin in prostatic cancer.

Ninety-two patients with histologically proved prostatic cancer were studied. Forty-six patients were treated with bacillus Calmette-Guérin (BCG) adjuvant immunotherapy, and 46 other patients, matched for stage and hormone therapy, served as controls. Survival from the time of histologic diagnosis was sixteen and one-half months longer (thirty-seven and one-half versus twenty-one months) in the BCG-treated patients. There was no mortality and only minimal morbidity. Changes in some immunologic parameters (white blood cell count, skin tests) suggest an immune response.

Aged↗
PubMed1979

Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.

An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan. In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded. Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases. In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period. The most common manifestation, observed in 15 further cases, was isolated optic atrophy. This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica. In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation. Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent. The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery. Older subjects tended to display more side effects. The full syndrome of subacute myelo-optic neuropathy was more frequent in women, but they tended to have taken greater quantities of the drug.

Adolescent↗
PubMed1979

Studies on the use of membrane markers for the differential diagnosis of malignant lymphomas.

Lymphoid cells isolated from lymph nodes, spleen and the peripheral blood were examined using the rosette test with sheep erythrocytes (E), immunofluorescent staining of the surface immunoglobulins (SmIg) and the combined test (SmIg + E). The studies were performed on 48 patients with untreated non-Hodgkin lymphoma, 14 Hodgkin patients, 5 patients with lymphadenitis and on 132 controls. In the control group the following percentages of B-T lymphocytes were obtained: blood (n = 100); T-68 +/- 9, B-20 +/- 6, 0-11 +/- 7, BT-1 +/- 1, lymph nodes (n = 24): T-62 +/- 13, B-19 +/- 11, 0-18 +/- 8, BT-1 +/- 1, spleens (n = 8): T-45 +/- 9, B-33 +/- 9, 0-23 +/- 7, BT-1 +/- 1. In non-Hodgkin lymphoma lymph nodes a statistically significant increase of B and 'null' cells was noted in comparison to controls and to the Hodgkin lymphoma group. The characteristics of the Hodgkin nodes did not differ significantly from controls. After arranging the non-Hodgkin lymphomas according to the Kiel classification it was observed that the low-grade malignant lymphomas subtype most often an immunological 'B type' and 'mixed B/0' type was present whereas the high-grade malignant lymphoma group showed a distinct majority of 'null' cells. It was concluded that the surface markers studied allow a differentiation in most cases between the non-Hodgkin lymphomas and other disorders of the lymphoid system. They are not sufficient to distinguish the subtypes of non-Hodgkin lymphomas but do give interesting information about the more exact nature of the disorder.

B-Lymphocytes↗
PubMed1978

Increased ratio between serum beta- and alpha-lipoproteins during diuretic therapy: an adverse effect?

1. The effect of diuretic therapy on serum lipids and lipoprotein fractions was evaluated in 16 normal or labile hypertensive subjects who received in cross-over fashion chlorthalidone, frusemide or mefruside, each for 4 weeks (group A); and in 13 patients with essential hypertension treated with chlorthalidone for 6 weeks (group B). 2. All three diuretics significantly increased the ratio between serum beta- and alpha-lipoprotein fractions. This was due to an increase of the serum beta-lipoprotein fraction while the alpha-lipoprotein fraction was not changed significantly (group A) or decreased (group B). Serum cholesterol or triglycerides tended to be increased, but mean changes were often not significant. 3. The observed alterations in serum lipoproteins are consistent with the possibility of an increased risk for coronary heart disease which could offset partly the beneficial effects of a lowered blood pressure in diuretic-treated patients with hypertension.

Blood Volume↗